Cara Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Cara Therapeutics (NASDAQ:CARA) has received 4 analyst ratings in the last quarter, with 3 being bullish and 1 indifferent. The average 12-month price target among these analysts is $4.12, with a high of $7.00 and a low of $1.00, marking a 70.57% decline from the prior average. Analysts from HC Wainwright & Co. and Piper Sandler have lowered their price targets, reflecting changes in market conditions and company performance. Cara Therapeutics is a biotech company developing therapeutics for pain and pruritus, facing revenue challenges with a -55.0% decline over 3 months as of September 30, 2023, but has a strong net margin of -576.08% and a low debt-to-equity ratio of 0.09.
December 19, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cara Therapeutics has seen a significant reduction in its average price target, indicating a bearish sentiment from analysts. Despite this, the company's strong net margin and low debt-to-equity ratio may provide some positive outlook.
The substantial decrease in the average price target suggests that analysts are less optimistic about the company's future stock performance. However, the company's financial health, indicated by its net margin and debt management, may mitigate some negative impact.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100